A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Status:
Recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
This study will test the safety of the study drug, repotrectinib, in combination with
chemotherapy (irinotecan and temozolomide) in children and young adults who have advanced or
metastatic solid tumors. We researchers will try to find the highest dose of the study drug
that causes few or mild side effects in study participants. When the researchers find this
dose, we will evaluate it in a different group of participants to find out whether
repotrectinib in combination with chemotherapy is an effective treatment for children and
young adults who have advanced/metastatic solid tumors. Another purpose of the study is to
look at the way the body absorbs, distributes, and gets rid of repotrectinib.